Detection of the Three Kunitz-Type Single Domains of Membrane-Bound Tissue Factor Pathway Inhibitor (TFPI) by Flow Cytometry

No abstract is available for this paper.

• Publication year

  1997

• Venue

  European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1515/cclm.1997.35.11.855PMID 9426344
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low molecular weight heparin

  2014cited by this paper
• Tissue factor pathway inhibitor.

  1999cited by this paper
• Effect of Cyclosporine A on the Release of Tissue Factor Pathway Inhibitor from Endothelial Cells in Heart Transplant Patients and Cell Culture

  1997cited by this paper
• Tissue factor pathway inhibitor

  1997cited by this paper
• Low-molecular-weight heparin.

  1997cited by this paper
• Heparin Reverses the Procoagulant Properties of Stimulated Endothelial Cells

  1996cited by this paper
• Tissue Factor Pathway Inhibitor

  1995cited by this paper
• Tissue factor pathway inhibitor: proposed heparin recognition region

  1995cited by this paper
• Tissue factor pathway inhibitor and the revised theory of coagulation.

  1995cited by this paper
• Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.

  1995cited by this paper
• Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.

  1995cited by this paper
• The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low‐molecular‐weight heparin

  1995cited by this paper
• Tissue factor pathway inhibitor and the current concept of blood coagulation

  1995cited by this paper
• Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.

  1994cited by this paper
• Synthesis of Tissue Factor Pathway Inhibitor in Human Synovial Cells and Chondrocytes Makes Joints the Predilected Site of Bleeding in Haemophiliacs

  1994cited by this paper
• The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

  1994cited by this paper
• Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.

  1994cited by this paper
• Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

  1993cited by this paper
• Cyclosporine and cremaphor modulate von Willebrand factor release from cultured human endothelial cells.

  1993cited by this paper
• Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.

  1993cited by this paper
• Structure of the human lipoprotein-associated coagulation inhibitor gene. Intro/exon gene organization and localization of the gene to chromosome 2.

  1991cited by this paper
• Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients.

  1990cited by this paper
• Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.

  1990cited by this paper
• Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor

  1988cited by this paper
• Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

  1988cited by this paper
• Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.

  1988cited by this paper
• Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

  1988cited by this paper
• Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.

  1987cited by this paper
• An alternative extrinsic pathway of human blood coagulation.

  1982cited by this paper

• Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix

  2021cites this paper
• Syndecan-3 and TFPI Colocalize on the Surface of Endothelial-, Smooth Muscle-, and Cancer Cells

  2015cites this paper
• Tissue Factor Pathway Inhibitor: Then and Now

  2014cites this paper
• TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity

  2013cites this paper
• Detached endothelial cells and microparticles as sources of tissue factor activity.

  2005cites this paper
• Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.

  2004cites this paper
• Glycosyl Phosphatidylinositol Anchorage of Tissue Factor Pathway Inhibitor

  2003cites this paper
• Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.

  2002cites this paper
• Characterization of the Association of Tissue Factor Pathway Inhibitor With Human Placenta

  2002cites this paper
• The Interaction Between the Coagulation System and the Systemic Inflammatory Mediators

  2002cites this paper
• Heparin Induces Synthesis and Secretion of Tissue Factor Pathway Inhibitor from Endothelial Cells In Vitro

  2000cites this paper
• Anomalies de la voie du facteur tissulaire en pathologie thrombotique veineuse

  2000cites this paper